Drug vials The debate around COVID vaccine patent waivers has been simmering slowly since October 2020, but the debate has been heating up since President Biden announced that the US would support the patent waiver. (Photo: Shutterstock)

The world is beginning to feel like it is returning to something approximating normalcy. In the US, all adults are now eligible to receive the COVID-19 vaccine, and nearly 150 million have. The Biden administration blew past its prior inoculation targets (100, then 200 million doses in his first 100 days) and has called an even more ambitious shot for this summer: 70% of all adults receiving one shot by July 4th.

That goal may be well within reach, with the Centers for Disease Control and Prevention (CDC) putting the US vaccination rate at about 60% of adults so far. What's more, Pfizer's vaccine is looking to be just as safe for citizens in the 12-15 age group as it has proven to be for the everyone else so far, bringing the percentage of the US population eligible to receive a vaccine upwards of 85%. This is a whole new cohort that can be protected against future infections, further reducing the threat of COVID-19.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.